SCHEMBL13429178

SCHEMBL13429178

O=c1cc(Oc2ccc(-c3ccncc3)cc2)c2ccccc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
MAPK14 Q16539 3/20 0.44
APOBEC3G Q9HC16 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
TNKS2 Q9H2K2 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
IMPDH2 P12268 1/20 0.41
TUBB4A P04350 2/20 0.41
TUBB P07437 2/20 0.41
TUBA3C P0DPH7 2/20 0.41
TUBA1B P68363 2/20 0.41
TUBA4A P68366 2/20 0.41
TUBB4B P68371 2/20 0.41
TUBB3 Q13509 2/20 0.41
TUBB2A Q13885 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429113 0.89 HPGD (0.57) HPGDSMN1; SMN2MAPK1HTTCYP1A2
SCHEMBL13429184 0.88 GRIN2D (0.45) HPGDSMN1; SMN2MAPK1HTTMAPK14
SCHEMBL13429115 0.87 HPGD (0.51) HPGDSMN1; SMN2MAPK1HTTKDM4E
SCHEMBL13429009 0.87 MKNK1 (0.47) HPGDSMN1; SMN2MAPK1HTTMAPK14
SCHEMBL13429118 0.85 HPGD (0.45) HPGDSMN1; SMN2MAPK1HTTCYP1A2
SCHEMBL13429004 0.85 CTSV (0.50) HPGDSMN1; SMN2MAPK1HTTMAPK14
SCHEMBL13429166 0.83 AKT1 (0.43) HPGDSMN1; SMN2MAPK1HTTCYP1A2
SCHEMBL13429120 0.83 TUBB4A (0.43) HPGDSMN1; SMN2MAPK1HTTCYP1A2
SCHEMBL2008835 0.82 HPGD (0.54) HPGDSMN1; SMN2MAPK1HTTCYP1A2
SCHEMBL13429176 0.81 KDM4E (0.46) HPGDSMN1; SMN2MAPK1HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA HPGD 2472/4885SMN1; SMN2 4072/4885MAPK1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.